Researched and Curated by Clinical and Scientific Experts.

Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.

Not all reports are available for public preview. For more information, please contact us.

Oleogel-S10 for Epidermolysis Bullosa

Oleogel-S10 is a semisolid gel containing 10% betulin-rich extract from birch bark and 90% refined sunflower oil. Betulin is a naturally occurring triterpene with medicinal properties believed to help modulate the inflammation response and encourage formation of new skin during wound healing. It is in development for the treatment of skin wounds associated with epidermolysis …

read more

Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donors or Haploidentical Family Donors for Sickle Cell Disease in Pediatric Patients

Focus of the Report: The focus of this report is on allogeneic hematopoietic stem cell transplantation (HSCT) utilizing alternative human leukocyte antigen (HLA)-matched donor sources in pediatric patients with sickle cell disease (SCD) without an HLA-matched sibling donor (MSD).

Technology D…

read more

Betibeglogene Autotemcel for Beta Thalassemia

Beta thalassemia is blood disorder caused by sequent variants in the beta-globin (HBB) gene that threaten normal production of hemoglobin. Lentiviral Autologous Beta-Globin Gene Therapy (Proposed Name: Zynteglo, formerly LentiGlobin) aims to reduce or eliminate the need for regular blood transfusions in patients with transfusion-dependent beta-t…

read more

Voxzogo (Vosoritide) for Achondroplasia

Vosoritide is a longer-acting C-type natriuretic peptide (CNP) analog that modulates activity of the fibroblast growth factor receptor 3 (FGFR3) by inhibiting a signaling pathway that mediates its effects, thereby stimulating endochondrial growth, resulting in enhanced growth velocity. It is indicated to increase linear growth in pediatric patients aged ≥ 5 years with achondr…

read more